Table 1 The correlation between clinicopathological variables and FNDC3B expression in PC patients

n

89

89

T stage, n (%)

T1

5 (2.8%)

2 (1.1%)

T2

14 (8%)

10 (5.7%)

T3

65 (36.9%)

77 (43.8%)

T4

3 (1.7%)

0 (0%)

N stage, n (%)

N0

33 (19.1%)

16 (9.2%)

N1

53 (30.6%)

71 (41%)

M stage, n (%)

M0

31 (36.9%)

49 (58.3%)

M1

1 (1.2%)

3 (3.6%)

Pathologic stage, n (%)

I

15 (8.6%)

6 (3.4%)

II

68 (38.9%)

79 (45.1%)

III

3 (1.7%)

0 (0%)

IV

1 (0.6%)

3 (1.7%)

Radiation therapy, n (%)

No

58 (35.6%)

60 (36.8%)

Yes

24 (14.7%)

21 (12.9%)

Primary therapy outcome, n (%)

PD

17 (12.1%)

33 (23.6%)

SD

6 (4.3%)

3 (2.1%)

PR

4 (2.9%)

6 (4.3%)

CR

39 (27.9%)

32 (22.9%)

Age, n (%)

≤ 65

38 (21.3%)

56 (31.5%)

> 65

51 (28.7%)

33 (18.5%)

Race, n (%)

Asian

6 (3.4%)

5 (2.9%)

Black or African American

3 (1.7%)

3 (1.7%)

White

80 (46%)

77 (44.3%)

Gender, n (%)

Female

42 (23.6%)

38 (21.3%)

Male

47 (26.4%)

51 (28.7%)

Histologic grade, n (%)

G1

24 (13.6%)

7 (4%)

G2

44 (25%)

51 (29%)

G3

17 (9.7%)

31 (17.6%)

G4

2 (1.1%)

0 (0%)

Residual tumor, n (%)

R0

59 (36%)

47 (28.7%)

R1

19 (11.6%)

34 (20.7%)

R2

3 (1.8%)

2 (1.2%)

Anatomic neoplasm subdivision, n (%)

Head

67 (37.6%)

72 (40.4%)

Other

22 (12.4%)

17 (9.6%)

Alcohol history, n (%)

No

29 (17.5%)

35 (21.1%)

Yes

55 (33.1%)

47 (28.3%)

Smoker, n (%)

No

40 (27.6%)

26 (17.9%)

Yes

38 (26.2%)

41 (28.3%)

History of chronic pancreatitis, n (%)

No

66 (46.5%)

63 (44.4%)

Yes

7 (4.9%)

6 (4.2%)

History of diabetes, n (%)

No

56 (38.1%)

53 (36.1%)

Yes

21 (14.3%)

17 (11.6%)